Overview
- Authors:
-
-
Seema Sethi
-
Department of Pathology, Wayne State University School of Medicine Karmanos Cancer Institute, Detroit, USA
- Addresses bone and brain metastasis in breast cancer
- Uniquely exemplifies molecular alterations with clinical implications
- Explains how targeting miRNAs could lead to novel therapeutic strategies?
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (6 chapters)
-
-
- Seema Sethi, Shadan Ali, Fazlul H. Sarkar
Pages 1-6
-
- Shadan Ali, Seema Sethi, Azfur S. Ali, Philip A. Philip, Fazlul H. Sarkar
Pages 7-22
-
- Manal Nizam, Saba Haq, Shadan Ali, Raagini Suresh, Ramzi M. Mohammad, Fazlul H. Sarkar
Pages 23-35
-
- Sharon K. Michelhaugh, Aliccia Bollig-Fischer, Sandeep Mittal
Pages 37-51
-
- Allen Kadado, Anil Sethi, Rahul Vaidya
Pages 53-64
-
- Aamir Ahmad, Fazlul H. Sarkar
Pages 65-75
-
About this book
This SpringerBrief gives the latest research on the role of miRNAs in breast cancer metastasis. MicroRNAs (miRNAs) are recently described small endogenous noncoding RNAs implicated in the posttranscriptional control of gene expression. These tiny molecules are involved in developmental, physiologic phenomenon as well as pathologic processes including cancers. In fact, miRNAs have emerged as critical regulators of cancer progression, invasion and metastasis. This is mainly because a single miRNA can affect several downstream genes and signaling pathways with oncogenic or tumor suppressor actions depending on the target genes affected. Due to this multimodal downstream signaling effects, these small endogenous molecules hold great promise in metastasis prevention and treatment. Modulating the activity of miRNAs can provide opportunities for novel cancer interventions. Targeting miRNAs could become a novel prognostic and therapeutic strategy to prevent the future development of metastasis. Thus, miRNAs could also serve as a potential targets for anti-metastatic therapy. Â The book explores how the expression of miRNAs in the primary tumor could be silenced using antagomirs (chemically modified anti-miRNA oligonucleotides), which could prevent the development of metastasis; whereas once metastasis develops then it could be treated with miRNA mimics for inducing its expression for the treatment. Therefore, development of miRNA-based prophylactic therapies could serve as precision and personalized medicine against future development of metastasis of breast and other cancers.
Authors and Affiliations
-
Department of Pathology, Wayne State University School of Medicine Karmanos Cancer Institute, Detroit, USA
Seema Sethi
About the author
Seema Sethi, MD, is a Research Assistant Professor in the Department of Pathology at Wayne State University. Dr Sethi’s research interests are in developing non-invasive molecular cytogenetic approaches for early diagnosis, prognosis and therapeutics of cancer, mainly breast, cervix and head and neck cancer. Currently, she is involved in several ongoing projects evaluating the role of biomarkers in the pathogenetic evolution of malignancies. Dr. Sethi has published 5 book chapters and 62 scientific papers and has received over 490 citations. She is the recipient of several poster and research awards.
